International Journal of Pharmaceutical Compounding

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

PreScription: Shortages Continue--Compounding Pharmacies Fill the Gap…Again!

Author(s): Allen Loyd V Jr

Issue: May/Jun 2023 - Volume 27, Number 3
View All Articles in Issue

Page(s): 180

PreScription: Shortages Continue--Compounding Pharmacies Fill the Gap…Again! Page 1

Download in electronic PDF format for $75

Abstract:

Related Keywords: Loyd V. Allen Jr., PhD, RPh, drug shortages, amoxicillin, drug supply problems, US Food and Drug Administration, FDA, Section 503B, Federal Food, Drug, and Cosmetic Act

Related Categories: LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
PreScription: Shortages Continue--Compounding Pharmacies Fill the Gap…Again! Allen Loyd V Jr	May/Jun 2023 Pg. 180
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
Allowing Compounding Pharmacies to Address Drug Shortages Broughel James	Mar/Apr 2022 Pg. 100-109
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
PreScription: Amoxicillin Shortage Continues: Compounding Pharmacies Filling the Gap! Allen Loyd V Jr	Mar/Apr 2023 Pg. 92
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers Allen Loyd V Jr, Williams LaVonn A	Jul/Aug 2012 Pg. 294-298
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe	Sep/Oct 2021 Pg. 358-362
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
The Role of Compounding Pharmacists During Drug Shortages Ofei Kelvin	Jul/Aug 2022 Pg. 298-301
PreScription: Discontinued Drugs and Drug Shortages Allen Loyd V Jr	Mar/Apr 2011 Pg. 92
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis Lyon Joanna	Nov/Dec 2012 Pg. 456-460
PreScription: Compounding for Drug Shortages Allen Loyd V Jr	May/Jun 2013 Pg. 180
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
Accuracy Considerations in Sterile Compounding Akers Michael J	Mar/Apr 2017 Pg. 133-142
PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry" Allen Loyd V Jr	Mar/Apr 2022 Pg. 92
Return to Top